Badanie cemiplimabu z chemioterapią i immunoterapią u osób z rakiem głowy i szyi
Badanie pilotażowe neoadiuwantowego leczenia cemiplimabem z chemioterapią podwójną platyną i cetuksymabem u pacjentów z resekcyjnym, miejscowo zaawansowanym rakiem płaskonabłonkowym głowy i szyi
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Lara Dunn, MD
- Numer telefonu: 646-608-3787
- E-mail: dunnl1@mskcc.org
Kopia zapasowa kontaktu do badania
- Nazwa: David Pfister, MD
- Numer telefonu: 646-888-4237
- E-mail: pfisterd@MSKCC.ORG
Lokalizacje studiów
-
-
New Jersey
-
Basking Ridge, New Jersey, Stany Zjednoczone, 07920
- Rekrutacyjny
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Kontakt:
- Lara Dunn, MD
- Numer telefonu: 646-608-3787
- E-mail: dunnl1@mskcc.org
-
Middletown, New Jersey, Stany Zjednoczone, 07748
- Rekrutacyjny
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Kontakt:
- Lara Dunn, MD
- Numer telefonu: 646-608-3787
-
Montvale, New Jersey, Stany Zjednoczone, 07645
- Rekrutacyjny
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
Kontakt:
- Lara Dunn, MD
- Numer telefonu: 646-608-3787
-
-
New York
-
Commack, New York, Stany Zjednoczone, 11725
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
-
Kontakt:
- Laura Dunn, MD
- Numer telefonu: 646-608-3787
-
Harrison, New York, Stany Zjednoczone, 10604
- Rekrutacyjny
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
Kontakt:
- Lara Dunn, MD
- Numer telefonu: 646-608-3787
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Lara Dunn, MD
- Numer telefonu: 646-608-3787
-
Rockville Centre, New York, Stany Zjednoczone, 11553
- Rekrutacyjny
- Memorial Sloan Kettering Nassau (Limited Protocol Activites)
-
Kontakt:
- Laura Dunn, MD
- Numer telefonu: 646-608-3787
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck that has arisen from the oral cavity, oropharynx, nasal cavity, paranasal sinuses, larynx, or hypopharynx
-
Clinical stage T1, N2-3; T2, N1-3, T3/T4a, Any N (AJCC, 8th ed.) without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis, for which standard-of-care treatment would entail surgical resection with adjuvant radiation +/- chemotherapy.
° Patients with recurrent and multiple primary head and neck cancers that are surgically resectable are eligible if the patient did not receive prior radiation or systemic therapy.
-
Disease must be amenable to surgical resection.
-
The patient must be a surgical candidate.
-
Adequate organ and bone marrow function documented by:
- Hemoglobin > 9.0 g/dL
- Absolute neutrophil count (ANC) >1.5 x 10^9/L
- Platelet count >100 x 10^9/L
- Serum creatinine <1.5 upper limit of normal (ULN) or estimated creatinine clearance (CrCl) >30 mL/min
- Adequate hepatic function:
-
Total bilirubin <1.5 x upper limit of normal ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 3 x ULN
-
Alkaline phosphatase (ALP) <2.5 x ULN Note: For patients with Gilbert syndrome, total bilirubin <3x ULN. Upper central must be documented appropriately as past medical history.
-
Men and woman >18 years old
-
Eastern cooperative oncology group performance status < 1 CPS ≥ 20 and
Inclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:
- Pathologically (histologically) proven diagnosis of oral cavity squamous cell carcinoma HPV-negative by p16 or ISH
- Clinical Stage will be limited to cT2 with cN0-N2b, cM0 with only 1 lymph node >2.0 cm in the short axis without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis.
- Curative intent surgical management is determined to require a free flap, mandibulectomy, glossectomy, or other significant surgical morbidity.
Exclusion Criteria:
- Prior radiation and systemic therapy for a head and neck cancer.
- Oral cavity cancer that is not amenable to surgical resection or the patient is not a surgical candidate.
- Active or prior documented autoimmune or inflammatory disorders that have been treated with steroids or immunomodulator therapy in the past 5 years.
Exceptions: Patients with vitiligo, type 1 diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that is resolved, or psoriasis it does not require systemic treatment are permitted.
-
Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressant medications within 14 days of treatment on study.
-
Receipt of live attenuated vaccine within 30 days prior initiating treatment on study.
-
Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
-
Any infection requiring hospitalization and/or intravenous antibiotic therapy within 2 weeks of the start of treatment.
-
Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency.
- Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection monitoring will be performed per local standards
- Patients with HBV (hepatitis B surface antigen positive; HBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months be on the last dose of Cemiplimab.
- Patients were HCV antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR, either spontaneously or in response to successful prior course of anti-HCV therapy) are permitted.
-
History of immune-related pneumonitis with the last 5 years.
-
History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of leuko-corticoids to assist with management.
-
Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.
-
Patients with a history of solid organ transplant (exception: corneal transplant)
-
Any medical comorbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that in the opinion of the investigator renders the patient unsuitable for participation in a clinical trial due to high safety risks.
-
Women with a positive serum or urine beta-hCG pregnancy test at screening/baseline visit. If positive, pregnancy must be ruled out by ultrasound for patient to be eligible.
-
Breast-feeding women
-
Women of childbearing potential who are sexually active and aren't willing to practice highly effective contraception prior to the first dose of Cemiplimab, during the study, and for at least 180 days after the last dose. Highly effective contraceptive measures include:
- Stable use of combined estrogen and progesterone containing hormonal contraception or progesterone and-only hormonal contraception associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening
- Intrauterine device; intrauterine hormone-releasing system
- Bilateral tubal ligation
- Vasectomized partner and/or
- Sexual abstinence
Exclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:
- History of head and neck cancer. This includes patients who present with a recurrence of a previously treated oral cavity squamous cell carcinoma.
- Synchronous primary squamous cell carcinomas of the oral cavity.
- Presence of diffuse oral mucosa dysplasia or leukoplakia that per the judgement of the clinical investigator represents a clinically and independent significant risk of developing a second oral cavity primary
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Head and Neck Squamous Cell Cancer/HNSCC
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible. |
Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8 Carboplatin AUC 5 on weeks 2, 5, and 8 Docetaxel 75mg/m2 on weeks 2, 5, and 8 Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s). Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of >0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines [2]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques. If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
Inne nazwy:
|
|
Eksperymentalny: Secondary Cohort
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible. |
Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 |
|
Eksperymentalny: Tertiary Cohort: Oral cavity squamous cell carcinoma (OCSCC)
A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC) |
Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10 Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37 |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of toxicities graded according to NCI CTCAE
Ramy czasowe: 1 year
|
The primary endpoint is safety and tolerability, which will be evaluated by a description of observed adverse events by grades. All toxicities will be graded according to NCI CTCAE, Version5.0. The regimen will be deemed safe and well tolerated if there are 2 or fewer DLTs out of 10 patients enrolled. A DLT is defined as any non-hematologic grade 3 or greater adverse event as defined by CTCAE v5.0 that is thought to be related to the addition of Cemiplimab to the combination of a platinum-doublet with cetuximab. |
1 year
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Lara Dunn, MD, Memorial Sloan Kettering Cancer Center
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Rak
- Rak, płaskonabłonkowy
- Rak płaskonabłonkowy głowy i szyi
- Nowotwory głowy i szyi
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Chemikalia nieorganiczne
- Związki chloru
- Związki azotu
- Kompleksy koordynacyjne
- Taksoidy
- Cyklodekan
- Diterpenes
- Związki platynowe
- Docetaksel
- Cetuksymab
- Karboplatyna
- Paklitaksel
- Cisplatyna
- Cemiplimab
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 20-445
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .